Device Trial Radar · NCT06608823
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,016
Planned (sponsor's estimate)
Start
Jun 18, 2025
Primary completion
Jun 2027
Study completion Feb 2036
Sponsor
- Lead sponsor
- JenaValve Technology, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 23, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate non-inferiority of the Trilogy Transcatheter Heart Valve (THV) System compared with surgical aortic valve replacement (SAVR) for treatment of subjects with clinically significant native aortic regurgitation (AR)
Conditions
- Aortic Regurgitation
- Aortic Valve Insufficiency
- Aortic Insufficiency
Interventions
Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV SystemDevice
Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device
SAVRDevice
SAVR using commercially available surgical prosthetic valves.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-Cause MortalityTime frame: 12 months
- All strokeTime frame: 12 months
- unplanned cardiac rehospitalizationTime frame: 12 months
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
CPMC Sutter Health
Burlingame, California · Recruiting
Scripps Health
La Jolla, California · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
37 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.